Q32 Bio's Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by Q32 Bio (QTTB).
Over the past two years, Q32 Bio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Bempikibart. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Bempikibart FDA Regulatory Timeline and Events
Bempikibart is a drug developed by Q32 Bio for the following indication: For Severe Alopecia Areata.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Bempikibart
- Announced Date:
- July 13, 2026
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.
AI Summary
Q32 Bio Inc. reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in patients with severe to very severe alopecia areata. In the prespecified mITT analysis, patients had a mean 35.3% reduction in SALT score from baseline, showing meaningful improvement in hair loss. At Week 36, 40.0% of patients in the mITT group and 30.3% in the ITT group reached a SALT-20 response, meaning they had at least 20% scalp hair loss improvement. The drug was generally well tolerated, with no new safety concerns.
Bempikibart, a fully human anti-IL-7Rα antibody, is designed to help rebalance the adaptive immune system by blocking IL-7 and TSLP signaling. Q32 Bio also said the drug showed favorable PK, PD, and ADA results. Based on these data, the company plans to move ahead with a registration-directed program in the first half of 2027.
Read Announcement- Drug:
- Bempikibart
- Announced Date:
- July 10, 2026
- Target Action Date:
- July 13, 2026
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc. announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.
AI Summary
Q32 Bio Inc. said it will release 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026. The study is evaluating bempikibart in patients with severe or very severe alopecia areata, a condition that causes hair loss. The company said the results will be shared in a conference call and webcast at 8:00 a.m. E.T. that same morning.
The event is expected to provide an update on how the treatment performed in the trial. Q32 Bio said the call will be available to investors and others interested in the data. More information can be found on the company’s website, Q32Bio.com.
Read Announcement- Drug:
- Bempikibart
- Announced Date:
- October 21, 2025
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc announced that it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA.
AI Summary
Q32 Bio Inc. has finished enrolling patients in Part B of its SIGNAL-AA Phase 2a trial for bempikibart, a fully human antibody against IL-7Rα. Strong patient demand led the company to increase enrollment from about 20 to 33 people with severe or very severe alopecia areata (AA). This milestone highlights both patient interest and the company’s ability to execute its clinical plan.
In Part B, participants receive a loading dose of 200 mg of bempikibart each week for four weeks, then 200 mg every other week through week 36, with safety and effects tracked through week 52. The trial will measure changes in the Severity of Alopecia Tool (SALT) score to see how well hair regrowth responds to treatment.
Early signs of clinical activity and faster steady-state drug levels have been observed. Q32 Bio expects topline data in mid-2026, which could support moving bempikibart into larger, pivotal trials if results are positive.
Read Announcement- Drug:
- Bempikibart
- Announced Date:
- April 30, 2025
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc. announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA.
AI Summary
Q32 Bio Inc. recently announced that the FDA has granted Fast Track designation to its investigational drug bempikibart (ADX‑914) for treating alopecia areata (AA). This designation recognizes the serious nature of AA and the significant unmet medical need in treating the condition. Bempikibart, a fully human anti‑IL‑7Rα antibody, works by blocking IL‑7 and TSLP signaling to help re-regulate the immune system. Its potential as a novel and differentiated treatment option is backed by promising clinical data observed in the ongoing Phase 2 SIGNAL‑AA trial.
The Fast Track status is designed to speed up the development and review process by allowing more frequent interactions with the FDA, which could ultimately lead to faster approval. This milestone underscores the commitment of Q32 Bio to deliver a potentially transformative therapy for patients suffering from AA.
Read Announcement- Drug:
- Bempikibart
- Announced Date:
- April 16, 2025
- Target Action Date:
- H1 2026
- Estimated Target Date Range:
- January 1, 2026 - June 30, 2026
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc. announced that SIGNAL-AA Part B topline data readout on-track for 1H'26 --
AI Summary
Q32 Bio Inc. announced that it is on track to report the SIGNAL-AA Part B topline data in the first half of 2026. This signal-phase trial is an important step in the clinical development of bempikibart, a fully human anti-IL-7Rα antibody designed to treat patients with alopecia areata. In Part B, approximately 20 patients with severe or very severe alopecia areata will be enrolled in an open-label study.
The dosing plan includes an initial loading regimen of 200mg given weekly for four weeks, followed by a maintenance dose of 200mg every other week over 32 weeks, for a total treatment period of 36 weeks, with a follow-up period extending to 52 weeks. The topline data readout is expected to provide insights into the efficacy and safety of bempikibart and help pave the way for future pivotal trials aimed at offering a new treatment option for patients.
Read Announcement- Drug:
- Bempikibart
- Announced Date:
- April 16, 2025
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc. announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA).
AI Summary
Q32 Bio Inc. announced a key milestone in the SIGNAL-AA Phase 2a clinical trial for its experimental drug, bempikibart, targeting alopecia areata (AA). The company has dosed the first patients in both the Part A open-label extension (OLE) and Part B portions of the study. The updated trial builds on earlier encouraging results from Part A, where patients demonstrated sustained responses and improvements in their Severity of Alopecia Tool (SALT) scores. In Part B, approximately 20 patients with severe AA will receive a treatment regimen that starts with a loading dose followed by a maintenance dose over 36 weeks, with follow-up continuing through 52 weeks. Q32 Bio believes that the favorable clinical activity and the well-tolerated safety profile of bempikibart could offer a new, differentiated treatment option for AA, potentially transforming care for patients if approved.
Read Announcement- Drug:
- Bempikibart
- Announced Date:
- March 11, 2025
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc. provided recent corporate updates.
AI Summary
Q32 Bio Inc., a clinical-stage biotechnology company, recently provided corporate updates focused on its bempikibart program for treating alopecia areata (AA). At the 2025 American Academy of Dermatology Annual Meeting, the company presented late-breaking Phase 2a Part A data showing encouraging clinical activity. Patients experienced continued hair growth responses even months after completing treatment, and bempikibart demonstrated a strong safety profile with durable results.
Building on these positive results, Q32 Bio is set to advance bempikibart in two additional studies: an open-label extension (OLE) of the SIGNAL-AA trial and Phase 2a Part B. The company plans to dose patients in the first half of 2025, with topline data from Part B expected in the first half of 2026. Financially, Q32 Bio reported $78 million in cash and cash equivalents as of December 31, 2024, providing runway into the second half of 2026.
Read Announcement- Drug:
- Bempikibart
- Announced Date:
- March 8, 2025
- Indication:
- For Severe Alopecia Areata
Announcement
Q32 Bio Inc. announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL.
AI Summary
Q32 Bio Inc. presented promising findings from Part A of its SIGNAL-AA Phase 2a trial for bempikibart at the 2025 American Academy of Dermatology Meeting. The trial focused on patients with severe alopecia areata and demonstrated significant improvements in hair loss, measured by a reduction in Severity of Alopecia Tool (SALT) scores. At week 24, patients treated with bempikibart experienced notable decreases in their SALT scores compared to the placebo group. Remarkably, many patients maintained or even deepened their hair regrowth after dosing ended at week 24, with continued positive results observed through week 36 and up to week 55 in some cases. The data further indicated that bempikibart is safe and well-tolerated, with supportive pharmacokinetic and receptor engagement results, emphasizing its potential as a long-lasting treatment option for alopecia areata.
Read Announcement
Q32 Bio FDA Events - Frequently Asked Questions
As of now, Q32 Bio (QTTB) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Q32 Bio (QTTB) has reported FDA regulatory activity for Bempikibart.
The most recent FDA-related event for Q32 Bio occurred on July 13, 2026, involving Bempikibart. The update was categorized as "Top-line results," with the company reporting: "Q32 Bio Inc announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling."
Currently, Q32 Bio has one therapy (Bempikibart) targeting the following condition: For Severe Alopecia Areata.
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:QTTB last updated on 7/13/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
